Last updated: September 8, 2026
The fixed-dose combination of cobicistat, elvitegravir, emtricitabine, and tenofovir disoproxil fumarate was marketed by Gilead Sciences as Stribild. Approved by the U.S. Food and Drug Administration in 2012, Stribild was an early once-daily, four-drug HIV-1 regimen that combined an integrase strand-transfer inhibitor with pharmacokinetic boosting and two nucleoside reverse-transcriptase inhibitors.
Stribild generated peak annual sales of roughly $1.1 billion before declining as Gilead shifted demand toward newer tenofovir alafenamide products, particularly Genvoya, and toward newer integrase-based regimens such as Biktarvy. The product remains commercially relevant as a low-cost generic-equivalent regimen, but its branded market position has weakened materially. Its patent risk is primarily a small-molecule generic-entry issue rather than a biologic or biosimilar issue.
What is Stribild and how does the four-drug combination work?
Stribild contains the following active ingredients:
| Component |
Dose per tablet |
Pharmacologic role |
| Elvitegravir |
150 mg |
HIV integrase strand-transfer inhibitor |
| Cobicistat |
150 mg |
CYP3A inhibitor used to increase elvitegravir exposure |
| Emtricitabine |
200 mg |
Nucleoside reverse-transcriptase inhibitor |
| Tenofovir disoproxil fumarate |
300 mg |
Nucleotide reverse-transcriptase inhibitor |
The regimen is administered once daily with food. FDA approval covered treatment of HIV-1 infection in adults without prior antiretroviral treatment and, later, certain virologically suppressed patients switching therapy. Stribild is not a complete treatment option for patients with chronic hepatitis B because discontinuation of emtricitabine and tenofovir can cause hepatitis B exacerbations. [1]
The product’s commercial logic was straightforward: one tablet, once daily, with elvitegravir providing integrase inhibition and cobicistat removing the need for a separate ritonavir booster. That positioning helped Gilead compete with Atripla, Complera, and raltegravir-based regimens during the shift toward integrase inhibitor therapy.
How did Stribild compare with Genvoya and Biktarvy?
Stribild lost commercial momentum because Gilead developed products with improved renal and bone safety profiles and stronger clinical positioning.
| Product |
Core regimen |
Tenofovir form |
FDA approval |
Commercial position |
| Stribild |
EVG/c/FTC/TDF |
TDF |
2012 |
Earlier-generation single-tablet regimen |
| Genvoya |
EVG/c/FTC/TAF |
TAF |
2015 |
Lower-tenofovir-exposure successor |
| Biktarvy |
Bictegravir/FTC/TAF |
TAF |
2018 |
Newer preferred single-tablet regimen |
Genvoya replaced TDF with tenofovir alafenamide, which generally produces lower circulating tenofovir concentrations and was positioned as having improved renal and bone tolerability. Biktarvy then offered a more modern integrase inhibitor, bictegravir, without the same dependence on cobicistat for pharmacokinetic boosting.
The competitive disadvantage of Stribild was therefore not limited to patent expiry. It also reflected product migration inside Gilead’s own HIV portfolio.
What were Stribild’s peak sales and financial trajectory?
Gilead reported the following approximate worldwide product sales for Stribild:
| Fiscal year |
Reported Stribild product sales |
| 2013 |
Approximately $368 million |
| 2014 |
Approximately $824 million |
| 2015 |
Approximately $1.0 billion |
| 2016 |
Approximately $1.1 billion |
| 2017 |
Approximately $1.0 billion |
| 2018 |
Approximately $853 million |
| 2019 |
Approximately $634 million |
| 2020 |
Approximately $465 million |
| 2021 onward |
No longer a major disclosed growth product |
Source figures are derived from Gilead annual reports and product-sale disclosures. [2-8]
The sales curve had four stages:
- Launch expansion from 2013 through 2015.
- Peak commercial contribution in 2016.
- Managed erosion after Genvoya gained adoption.
- Accelerated decline after Biktarvy became a leading Gilead HIV product.
Stribild was economically important because it established Gilead’s single-tablet integrase franchise. Its later value was partly strategic: it enabled switching patients into Genvoya and helped Gilead maintain formulary relationships while newer products gained share.
When did Stribild lose exclusivity?
Stribild did not lose all commercial protection on a single date. Exclusivity consisted of FDA regulatory exclusivity, Orange Book-listed patents, formulation claims, active-ingredient claims, and method-of-use claims.
The key timing points were:
| Event |
Date |
| FDA approval of Stribild |
August 27, 2012 |
| Likely five-year new-chemical-entity exclusivity period |
Through August 2017 |
| Genvoya approval |
November 5, 2015 |
| Biktarvy approval |
February 7, 2018 |
| Main Stribild patent-risk period |
Late 2020s, depending on patent and jurisdiction |
| Commercial erosion |
Began before formal patent expiry because of internal product substitution |
Stribild’s commercial exclusivity was effectively weakened before patent expiry. Genvoya and Biktarvy gave prescribers newer options, while generic versions of the individual components reduced the strategic value of the branded combination.
What patents protect Stribild?
The relevant estate includes patents covering elvitegravir, cobicistat, pharmaceutical compositions, fixed-dose combinations, and treatment methods. The principal U.S. patent families associated with the regimen include the following:
| Patent |
General subject matter |
Reported expiration profile |
| U.S. Patent No. 7,598,356 |
Elvitegravir-related chemistry and use |
Mid-2020s, subject to patent-term adjustments |
| U.S. Patent No. 8,592,397 |
Combination and pharmaceutical-composition protection |
Late 2020s |
| U.S. Patent No. 8,759,345 |
Cobicistat and combination-related claims |
Late 2020s |
| U.S. Patent No. 9,340,579 |
Additional composition and regimen protection |
Early 2030s in certain claim scopes |
The exact enforceable date depends on the patent, terminal disclaimers, patent-term adjustment, pediatric extension, claim scope, and Orange Book listing. Orange Book records should control the operative U.S. analysis for an ANDA applicant. [9]
The estate is stronger than a single compound patent because it combines multiple layers:
- Elvitegravir composition claims.
- Cobicistat composition and boosting claims.
- Fixed-dose tablet claims.
- Pharmaceutical-composition claims.
- Methods for treating HIV with the combination.
- Manufacturing and formulation claims.
The weakness is that many active ingredients are available separately as mature generic products. A challenger can target the combination product without needing to recreate Gilead’s entire HIV franchise.
What formulation patents protect the product?
Formulation protection focuses on the physical tablet and the co-formulation of four chemically distinct components. The technical challenges include:
- Maintaining chemical stability among the active ingredients.
- Achieving uniform dissolution across the tablet.
- Controlling elvitegravir and cobicistat exposure.
- Preserving food-dependent bioavailability characteristics.
- Managing tablet size and manufacturing yield.
- Preventing degradation of the tenofovir component.
These claims can delay or complicate generic entry even when individual active ingredients are off patent. Their commercial strength depends on whether the claims require a narrow excipient system or cover a broad fixed-dose combination.
Genvoya also created a separate formulation and composition estate because TAF is chemically and clinically distinct from TDF. A generic Stribild entrant would not automatically obtain permission to market Genvoya.
What method-of-use patents cover Stribild?
Method-of-use claims cover administration of the regimen for HIV-1 treatment, including treatment-naive and virologically suppressed populations. In practice, method-of-use patents are less powerful than composition claims when the ANDA applicant can use a section viii statement to carve out patented indications.
For HIV medicines, the broadest commercial protection generally comes from the composition and fixed-dose tablet claims. Method-of-use patents can still create litigation exposure, particularly where the label includes a patented patient population or treatment protocol.
Which companies challenged or could challenge Stribild patents?
The likely challenger group consists of established generic antiretroviral manufacturers with experience in complex oral products:
- Teva Pharmaceuticals.
- Viatris and Mylan-related entities.
- Lupin.
- Cipla.
- Aurobindo.
- Hetero and related global suppliers.
- Apotex and other ANDA applicants.
Publicly disclosed Stribild-specific Paragraph IV litigation has been less commercially prominent than litigation involving Gilead’s TAF products, hepatitis C drugs, or tenofovir disoproxil products. The absence of highly visible litigation does not remove generic-entry risk. An applicant may use a Paragraph III certification, wait for relevant patents to expire, settle with the patent holder, or challenge only selected listed patents.
What is the Orange Book status of Stribild?
Stribild is an FDA-approved small-molecule drug listed under NDA 203100. Its Orange Book position is based on the listed patents that Gilead submitted for the approved product and related labeling.
Orange Book analysis should distinguish:
- Patents listed against Stribild itself.
- Patents listed against Genvoya.
- Patents covering individual active ingredients.
- Patents with claims that do not necessarily block every generic formulation.
- Expired patents versus patents with remaining enforceable claims.
A generic applicant must address each relevant listed patent through a Paragraph I, II, III, or IV certification. A Paragraph IV notice can trigger a 30-month stay if the patent holder files an infringement action within the statutory period. [10]
Are there biosimilar risks for Stribild?
There is no biosimilar pathway for Stribild. The product is a chemically synthesized small-molecule fixed-dose combination, so competition proceeds through the ANDA pathway rather than the biologics license application and biosimilar pathways.
The relevant risks are:
- ANDA approval.
- Paragraph IV patent litigation.
- Authorized-generic supply.
- Product substitution at pharmacies and payers.
- Generic competition against individual components.
- International generic competition outside the United States.
This distinction matters commercially. Biosimilar entry often requires manufacturing comparability and interchangeability work. Stribild competition is primarily a bioequivalence, patent, manufacturing, and regulatory-label issue.
What generic launch scenarios exist for Stribild?
Three launch scenarios are commercially plausible.
Scenario 1: Delayed entry after patent expiry
A generic applicant waits until the last blocking patent expires. This reduces litigation expense but sacrifices the 180-day first-filer advantage and allows competing ANDA applicants to prepare for simultaneous entry.
Scenario 2: At-risk Paragraph IV launch
A first filer launches before final patent expiry after receiving tentative or final approval. The applicant assumes damages risk if Gilead prevails. This scenario is less attractive where several patents remain and the branded market has already contracted.
Scenario 3: Settlement-based entry
Gilead and the generic applicant agree on a future launch date, an authorized-generic arrangement, or other commercial terms. HIV antiretroviral settlements have historically required close scrutiny under antitrust and Hatch-Waxman standards.
The financial incentive for an early challenge is lower than it was at Stribild’s peak because branded revenue has declined. The patent holder’s incentive to litigate may also be lower if Genvoya and Biktarvy have already captured most commercially valuable patients.
What manufacturing and intellectual-property barriers remain?
The main manufacturing barriers are technical rather than biological. A successful manufacturer must produce a stable four-component tablet with reproducible bioequivalence and acceptable dissolution.
Key risks include:
- Elvitegravir’s low aqueous solubility.
- Cobicistat’s interaction with formulation excipients.
- Multi-component stability.
- Scale-up consistency.
- Analytical methods for impurities and degradation products.
- Supply-chain reliability for four active ingredients.
- Regulatory review of process changes.
These barriers can reduce the number of effective competitors even after patent expiry. They do not create the same entry barriers as injectable biologics or complex drug-device products.
How strong is the Stribild patent estate?
The estate is moderate to strong historically, but its present commercial strength is lower than its legal breadth suggests.
| Factor |
Assessment |
| Compound protection |
Meaningful for elvitegravir and cobicistat, but aging |
| Fixed-dose combination protection |
Important and commercially relevant |
| Formulation protection |
Potentially meaningful for complex co-formulation |
| Method-of-use protection |
Useful but more vulnerable to label carve-outs |
| Generic substitution risk |
High after effective blocking claims expire |
| Biosimilar risk |
Not applicable |
| Lifecycle-management strength |
Limited against Biktarvy’s clinical and commercial advantages |
| Current revenue protection |
Low relative to peak years |
Gilead’s strongest defense was lifecycle management rather than indefinite protection of Stribild itself. Moving patients to Genvoya and then Biktarvy reduced the economic impact of eventual generic entry.
What licensing deals affect the product?
Gilead’s HIV business has been shaped by licensing and collaboration arrangements involving compounds, technologies, and regional commercialization. Stribild itself was developed and commercialized within Gilead’s HIV franchise, with cobicistat and elvitegravir integrated into Gilead’s product strategy.
The most commercially important external relationships concern the underlying antiretroviral technology and regional distribution rather than a major co-commercialization deal for Stribild. Generic licensing or settlement agreements can become more relevant near entry dates, particularly where Gilead seeks to control launch timing or supply an authorized generic.
What is the FDA regulatory status?
Stribild is FDA-approved for HIV-1 treatment in specified adult populations. The product is not a biologic, does not use the biosimilar pathway, and is subject to NDA and Orange Book regulation.
Its regulatory status is distinct from:
- Genvoya, which contains TAF rather than TDF.
- Biktarvy, which contains bictegravir rather than elvitegravir and does not use cobicistat.
- Truvada, which contains FTC/TDF without an integrase inhibitor or booster.
- Atripla, which contains efavirenz, FTC, and TDF.
The product’s regulatory age and declining use reduce its probability of generating new clinical-label expansion value.
How does Stribild compare with competing HIV regimens?
| Product |
Main advantage over Stribild |
Main limitation |
| Genvoya |
TAF-based renal and bone profile |
Cobicistat interactions remain |
| Biktarvy |
Strong efficacy, simple once-daily dosing, no booster |
Higher branded cost before generic competition |
| Triumeq |
Dolutegravir-based option without tenofovir |
Abacavir requires HLA-B*5701 screening and cardiovascular-risk assessment |
| Dovato |
Two-drug regimen |
Not appropriate for every patient or clinical circumstance |
| Generic FTC/TDF combinations |
Lower cost |
Do not provide the same complete four-drug regimen |
| Atripla |
Established low-cost generic availability |
Efavirenz tolerability and neuropsychiatric limitations |
Biktarvy is the principal internal competitor. Its success reduced the value of Stribild before generic entry became the dominant issue.
What revenue exposure remains?
Stribild no longer represents a major growth driver for Gilead. The remaining value is concentrated in:
- Residual branded prescriptions.
- Patients stable on the existing regimen.
- Markets with slower adoption of TAF or bictegravir.
- Government and international procurement.
- Potential authorized-generic economics.
- Portfolio leverage from the underlying HIV franchise.
The principal financial risk is therefore cannibalization and substitution, not a sudden standalone patent cliff. Gilead has already transferred much of the regimen’s economic value to newer products.
Key Takeaways
- Stribild is the branded fixed-dose combination of cobicistat, elvitegravir, emtricitabine, and TDF.
- FDA approval occurred on August 27, 2012.
- Annual sales peaked at approximately $1.0 billion to $1.1 billion in 2015-2016.
- Revenue declined as Genvoya and Biktarvy displaced the product.
- The product has small-molecule generic risk, not biosimilar risk.
- Patent protection includes compound, composition, formulation, and method-of-use claims.
- Orange Book and patent-term data control the U.S. launch analysis.
- Generic-entry economics are weaker than during the product’s peak because the branded market has already contracted.
- Genvoya and Biktarvy are the most important competitive products.
- Stribild’s remaining value lies in residual demand, global access markets, and potential generic or authorized-generic supply.
FAQs
What is the generic name for Stribild?
The generic name is the fixed-dose combination of elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate.
Is Stribild the same as Genvoya?
No. Stribild contains TDF, while Genvoya contains TAF. Both contain elvitegravir, cobicistat, and emtricitabine.
Does Stribild still have patent protection?
Yes. Patent protection depends on the specific patent, claim, jurisdiction, terminal disclaimer, and applicable patent-term adjustment. U.S. Orange Book records provide the operative listing for ANDA analysis.
Can a generic manufacturer make Stribild without a biosimilar application?
Yes. Stribild is a small-molecule drug. A generic manufacturer would generally use the ANDA pathway and establish bioequivalence rather than pursue a biosimilar application.
Why did Stribild sales decline before generic entry?
Sales declined because Gilead shifted patients toward Genvoya and Biktarvy, which offered newer clinical profiles and stronger commercial positioning. The decline was therefore driven by internal product substitution as well as eventual generic competition.
References
- U.S. Food and Drug Administration. (2012). FDA approves Stribild for HIV treatment. https://www.fda.gov
- Gilead Sciences, Inc. (2014). 2013 annual report.
- Gilead Sciences, Inc. (2015). 2014 annual report.
- Gilead Sciences, Inc. (2016). 2015 annual report.
- Gilead Sciences, Inc. (2017). 2016 annual report.
- Gilead Sciences, Inc. (2018). 2017 annual report.
- Gilead Sciences, Inc. (2019). 2018 annual report.
- Gilead Sciences, Inc. (2020). 2019 annual report.
- U.S. Patent and Trademark Office. (2024). Patent Center and patent-term information for Gilead HIV drug patents. https://patentcenter.uspto.gov
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
